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Objective. To investigate the pathophysiological role of pro- and anti-inflammatory cytokines in primary multiple sclerosis-related
fatigue. Methods. Fatigued and non-fatigued patients with multiple sclerosis (MS) were recruited and their cytokine profiles
compared. Patients with secondary fatigue were excluded. Fatigue was assessed with the self-reported Checklist Individual Strength
(CIS20r), subscale fatigue. A CIS20r fatigue cut-off score of 35 was applied to differentiate between non-fatigued (CIS20r fatigue
≤34) and fatigued (CIS20r fatigue ≥35) patients with MS. Blood was collected to determine the serum concentrations of pro-
inflammatory cytokines (IL-1𝛽, IL-2, IL-6, IL-8, IL-12p70, IL-17, TNF𝛼, and IFN-𝛾) and anti-inflammatory cytokines (IL-4, IL-5,
IL-10, and IL-13). We controlled for the confounding effect of age, gender, duration of MS, disease severity, type of MS, and use of
immunomodulatory drugs. Results. Similar cytokine levels were observed between MS patients with (𝑛 = 21) and without fatigue
(𝑛 = 14). Adjusted multiple regression analyses showed a single significant positive relationship, that of IL-6 with CIS20r fatigue
score. The explained variance of the IL-6 model was 21.1%, once adjusted for the confounding effect of age. Conclusion. The pro-
inflammatory cytokine interleukin-6 (IL-6) may play a role in the pathophysiology of primary fatigue in patients with MS. Trial
Registrations. ISRCTN69520623, ISRCTN58583714, and ISRCTN82353628.
1. Introduction
Multiple sclerosis (MS) is an inflammatory demyelinating
and neurodegenerative disease of the central nervous system
[1]. The age of onset of MS is usually between the age of
20 and 40, and MS affects females twice as often as males
[1]. Prevalence and incidence are greater in higher northern
and southern latitudes [1, 2]. The disease course of MS can
be divided into three main subtypes, known as relapsing
remitting (RR), secondary progressive (SP), and primary
progressive (PP) [1, 2].
Fatigue is one of themost prominent and disabling symp-
toms of MS and is independent of MS subtype, restricting
patients’ societal participation and performance in daily life
at home, at work, and in leisure activities [3, 4]. MS-related
fatigue can be subdivided into primary and secondary fatigue
[4, 5]. Primary fatigue relates to specific pathophysiological
mechanisms that are the direct consequence of the MS
disease process, such as demyelination and axonal loss [5],
while secondary fatigue can be attributed to symptoms or
an accumulating disease burden, including sleep disorders,
depression, and the side effects of therapy [5]. It is often
difficult to differentiate between primary and secondary
fatigue as both can be simultaneously present in a patient
and may impact each other [5, 6]. A common example is
depression due to the major impact of primary fatigue on
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A better understanding of the pathophysiological mech-
anisms of primary fatigue would allow the development of
effective treatments. A first step towards this goal requires
understanding of the biological correlates of primary MS-
related fatigue. Optimal pharmacological treatments for MS-
related fatigue are currently unavailable and oral therapies
such as Amantadine or Pemoline are usually only partially
effective [7]. Limited insight into the pathophysiological
mechanisms of primary MS-related fatigue is probably an
important contributory factor to the current lack of treatment
options. In this study we specifically focus on primary MS-
related fatigue by excluding secondary fatigue causes.
Multiple mechanisms have been proposed to play a
role in primary MS-related fatigue, including a chronic
imbalance in inflammatory factors, [5, 8]. Both the serum
levels of pro-inflammatory cytokines and fatigue increase
during a relapse [3, 4]. Moreover, fatigue is one of the
side effects of immune-modulatory medications such as
interferon-𝛽 [5, 9]. Furthermore, an association has been
found between fatigue and levels of inflammatory cytokines
in other (auto)immune-related diseases, such as rheuma-
toid arthritis (RA), human immunodeficiency virus (HIV),
and systemic lupus erythematosus (SLE) [8, 10, 11]. Finally,
cytokines have been related to sleep disorders including sleep
apnea syndrome, narcolepsy, idiopathic hypersomnia, and
chronic fatigue syndrome [11, 12].
The aim of this study was to explore a possible relation-
ship between serum concentrations of pro- and anti-inflam-
matory cytokines and primary MS-related fatigue through
the quantification of twelve different serum cytokines by
electrochemiluminescence-based multiplex immunoassay.
2. Materials and Methods
2.1. Design. Fatigued andnon-fatigued patientswithMSwere
recruited and their cytokine profiles compared. In addition,
pro- and anti-inflammatory cytokine concentrations were
related to the level of MS-related fatigue.
2.2. Participants. All patients included in the study met the
following inclusion criteria: (a) definitive diagnosis of MS,
(b) age between 18 and 70 years, (c) being ambulatory,
and (d) normal thyroid function (blood levels of thyroid
stimulating hormone of 0.3–4.5mU/L).The exclusion criteria
for the study were (a) evident signs of an exacerbation or
corticosteroid treatment in the past 3 months, (b) current
infections (abnormal leukocytes and C-reactive protein in
blood), (c) anaemia (abnormal haemoglobin andhaematocrit
in blood), (d) depression (Hospital Anxiety and Depression
Scale, depression score > 11), (e) primary sleep disorders,
(f) severe comorbidity (Cumulative Illness Rating Scale
(CIRS) item score of ≥3) [13, 14], (g) current pregnancy or
having given birth in the past 3 months, (h) pharmacological
treatment for fatigue that was started in the past 3 months
(e.g., Amantadine,Modafinil, Ritalin, and Pemoline), (i) non-
pharmacological therapies for fatigue that took place in the
past 3 months.
Non-fatigued patients, defined as having a score of 34 or
less on the Checklist Individual Strength (CIS20r) subscale
fatigue,were recruited from theDepartment of Rehabilitation
Medicine of the VU University Medical Center or the Reha-
bilitationCenterHeliomare [15, 16]. Patients with a score of 35
or more on the CIS20r subscale fatigue were recruited from
the Treating Fatigue in MS research programme (TREFAMS-
ACE) [16, 17].
The study protocol was approved by the Medical Ethics
Committees of the participating centres, with the Medical
Ethics Committee of the VU University Medical Center,
Amsterdam, acting as the principal review board. Written
informed consent was obtained from each participant prior
to entering the study.
2.3. Clinical Scores. All patients underwent neurological
screening to classify the disease course and to determine
the Expanded Disability Status Scale (EDSS) score [18].
Furthermore, the presence and severity of comorbidities were
quantified using the CIRS [13, 14]. Data on age, gender, and
the use of disease-modifying drugs were collected.
2.4. Fatigue. Fatigue was measured with the CIS20r, subscale
fatigue [15, 16]. The CIS20r is a multidimensional question-
naire that consists of 20 items, divided into 4 dimensions
of fatigue and related behavioural aspects: (a) the subjective
experience of fatigue (8 items), (b) reduction in motivation
(4 items), (c) reduction of physical activity (3 items), and (d)
reduction in concentration (5 items). The CIS20r focuses on
fatigue in the past 2 weeks and each item is answered using a
7-point scale.The CIS20r fatigue score is a sum score that can
vary between 8 and 56 points, the latter corresponding to the
maximum level of fatigue [15, 16].
2.5. Blood Draw and Sample Handling. Blood was drawn
from the participants between 9:00 and 15:00 and at three
centres, using the same study protocol and BD Vacutainer
plastic serum tubes (BD, New Jersey, USA). The tubes were
processed within 1 hour by centrifugation at 1800×g for
10 minutes and subsequently stored in polypropylene tubes
(Sarstedt, Germany) at −80∘C.
2.6. Multiplex Cytokine Assay. Evaluation of multiple
cytokines took place at the neurochemistry lab of the
VU University Medical Center, using the ultrasensitive
human Th1/Th2-10 plex kit (Meso Scale Discovery (MSD),
Maryland, USA). This kit allows the detection of IL-1𝛽, IL-2,
IL-4, IL-5, IL-8, IL-10, IL-12p70, IL-13, TNF-𝛼, and IFN-𝛾.
The cytokines IL-6 and IL-17 weremeasured using the single-
plex human ultrasensitive IL-6 and the human ultrasensitive
IL-17 kits (MSD). The MSD kits were run according to the
manufacturer’s guidelines. The chemiluminescence signal
was measured and the read-out performed on a Sector
Imager 6000 (MSD). The cytokine concentrations were
determined using Discovery Workbench 3.0.18 software
from the instrument and a log-log curve fit model. Overall,
the average lower limit of detection in serum for Th1/Th2-10
plex kit was 0.67 pg/mL. The overall coefficient of variation
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(CV) for samples performed in duplicate was <20%. The
lower limits of detection of the IL-6 and IL-17 kits were
0.7 pg/mL and 0.2 pg/mL, respectively, with an average CV
of <10% and <13%.
2.7. Statistical Analysis. Group differences with regard to
demographic and disease-related variables were analysed
using the independent 𝑡-test, Mann-Whitney 𝑈 test, or Chi-
square test. Because cytokine concentrations were not nor-
mally distributed, the cytokines of the non-fatigued and the
fatigued patients were compared for statistical significance
using the Mann-Whitney 𝑈 test. Log-transformed cytokine
values were used in multiple linear regression analyses, with
the CIS20r fatigue score as a continuous outcome measure
[19]. Age, gender, duration of MS, disease severity (EDSS),
MS subtypes, and the use of immunomodulatory drugs were
included in the multiple regression analyses to adjust for
confounding when appropriate, that is, when these variables
individually changed the univariate (i.e., unadjusted) regres-
sion coefficient of each cytokine by more than 10% [20]. All
analyses were carried out in SPSS 20.0.
3. Results
3.1. Participants. Thirty-five patients with MS (24 female, 11
male; mean age 44 ± 9.6 years) were eligible to participate.
Twenty-six patients had relapsing remittingMS, four patients
had secondary progressiveMS, and four patients had primary
progressive MS (Table 1). The type of MS was not specified
for one patient. The median disease duration was 8.6 years
(minimum-maximum 0.2–21.2 years). Eighteen patients had
no or mild neurological disability, defined as an EDSS of <3,
while sixteen patients had moderate or severe disability
defined as an EDSS of ≥3. The EDSS was missing for one
patient. Sixteen patients had no comorbidity; that is, the
total CIRS score was 0, while 19 patients had one or more
non-severe comorbid conditions that require (pharmaco-
logical) treatment but have a good prognosis. Seventeen
of the patients were receiving disease-modifying immune-
modulatory treatment, for example, interferon beta-1a, inter-
feron beta-1b, glatiramer acetate, or natalizumab. Twenty-
one participants were severely fatigued (CIS20r fatigue ≥
35), and 14 patients were classified as non-fatigued (CIS20r
fatigue ≤34). Patients in the fatigue group also showed
reduced concentration, motivation, and physical activity on
the CIS20r (Table 1). The fatigue and non-fatigue groups did
not differ significantly in age, gender, duration of MS, type
of MS, EDSS, or use of immunomodulatory drugs. Thus, the
potentially confounding variables were equally distributed
among the fatigued and non-fatigued patients.
3.2. Cytokines in MS Patients with and without Primary
Fatigue. The serum concentrations of pro-inflammatory (IL-
1𝛽, IL-2, IL-6, IL-8, IL-12p70, IL-17, TNF𝛼, and IFN-𝛾) and
anti-inflammatory cytokines (IL-4, IL-5, IL-10, and IL-13) are
summarized in Table 1. No differences in the profiles of pro-
inflammatory cytokines and anti-inflammatory cytokines
were observed between the fatigued andnon-fatigued groups.
3.3. Regression Analyses of Cytokines with CIS20r Fatigue.
Multiple regression analyses of the 12 serum cytokine concen-
trations (log 10 transformed) showed that pro-inflammatory
IL-6 was the only cytokine significantly related to the CIS20r
fatigue score (𝑃 value 0.009) (Table 2). Age was identified as
confounder of the relationship between IL-6 and the CIS20r
fatigue (10% change of the univariate regression coefficient
of IL-6). The explained variance (𝑅2) of IL-6 on fatigue,
adjusted for age, was 21.1%.None of the potential confounders
age, gender, duration of MS, disease severity, type of MS,
and immunomodulatory drugs showed an independent and
significant regression coefficient with the CIS20r fatigue
score.
4. Discussion
In this study we investigated the pathophysiological role
of pro- and anti-inflammatory cytokines in primary MS-
related fatigue. Comparison of the serum cytokine levels of 21
patients with severe fatigue with those of 14 patients with low
fatigue scores showed only small, non-significant differences.
Moreover,multiple regression analysis showed no association
of the cytokines IL-1𝛽, IL-2, IL-4, IL-5, IL-8, IL-12p70, IL-
17, TNF𝛼, IFN-𝛾, IL-10, and IL-13 with primary MS-related
fatigue, with the exception of the pro-inflammatory cytokine
IL-6. Furthermore, fatigue scoreswere not associatedwith the
patient characteristics age, gender, disease duration, type of
MS, EDSS, or the use of immunomodulatory drugs.
The major strength of this pathophysiological study was
that we focussed on primary MS-related fatigue by exclud-
ing secondary fatigue. This allowed us to assess primary
fatigue-associated factors and thus gain insight into the
pathophysiological mechanisms affecting primary fatigue.
Furthermore, we succeeded in including fatigued and non-
fatigued patients. An additional strength was the comparison
of patients with the same disease, rather than using a healthy
control group or a group of patients with another chronic
disease. Moreover, we assessed a broad range of different pro-
and anti-inflammatory cytokines by applying the mesoscale
discovery multiplex platform, which has been shown in
various studies to allow a very reliable and sensitivemultiplex
assessment of cytokines in body fluids [21–23]. Finally, the
associations of cytokines with primary MS-related fatigue
were adjusted for potential bias due to confounding factors.
The limitations of this study should also be considered,
the main limitations being the small sample of MS patients
and the large number of statistical tests in the same set of
patients. Due to our small sample size of 35 participants
and the anticipated multicollinearity between cytokines, we
decided to run 12 “independent” models, with the same
fatigue outcome, and in each model one cytokine as explana-
tory determinant. A close inspection of the correlation
matrix of the cytokines showed highmulticollinearity (>0.70)
between the anti-inflammatory cytokines. However, most of
the correlations of the pro-inflammatory cytokines were low
and non-significant. With respect to IL-6, the highest cor-
relation was with the log-transformed IL-1𝛽, with a Pearson
correlation coefficient of −0.358. This might explain why we
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Table 1: Clinical characteristics and cytokine scores of fatigued and non-fatigued multiple sclerosis patients.





Age, mean (sd) (years) 43.3 (10.6) 45.0 (8.2) 0.60b
Duration of MS, median (min–max) (years) 8.7 (0.2–20.5) 8.6 (1.0–21.2) 1.00c
Type of MS∗ 0.81a
Relapsing remitting 15 11
Primary or secondary progressive 5 3
EDSS, median (IQ)∗ 2.25 (1.13–3.38) 2.75 (1.38–3.13) 0.99c
Immunomodulatory treatment 0.89aa
Interferon beta 7 3




Fatigue 46.2 (5.0) 20.6 (7.5) 0.00b
Concentration 19.3 (9.9) 16.6 (8.9) 0.40b
Motivation 14.1 (5.4) 10.4 (6.2) 0.08b
Physical activity 12.0 (5.0) 7.9 (3.7) 0.01b
Pro-inflammatory cytokines
Median (min–max) (pg/mL)
IL-1𝛽 0.3 (0.1–1.1) 0.3 (0.1–2.9) 0.65c
IL-2 0.2 (0.0–1.1) 0.3 (0.0–1.4) 0.21c
IL-6 0.4 (0.2–9.7) 0.3 (0.2–0.9) 0.13c
IL-8 10.0 (5.2–33.9) 10.0 (3.3–18.5) 0.70c
IL12p70 4.4 (0.9–117.6) 3.4 (0.48–229.0) 0.52c
IL-17 0.3 (0.0–1.7) 0.2 (0.0–0.8) 0.28c
TNF-𝛼 7.3 (4.2–12.5) 6.7 (5.1–11.8) 0.78c
IFN-𝛾 0.8 (0.2–75.7) 1.0 (0.4–5.0) 0.70c
Anti-inflammatory cytokines
Median (min–max) (pg/mL)
IL-4 1.2 (0.6–2.6) 1.1 (0.6–3.9) 0.75c
IL-5 0.5 (0.2–16.0) 0.8 (0.2–15.6) 0.54c
IL-10 2.3 (0.5–42.9) 2.0 (0.9–60.8) 0.75c
IL-13 2.2 (0.6–57.6) 3.3 (0.7–51.0) 0.70c
𝑃 values according to aChi-square test, bindependent 𝑡-test, and cMann-Whitney 𝑈 test.
aaChi-square test comparing use and nonuse of immunomodulatory treatment.
∗One missing value.
IQ: interquartiles; CIS20r: Checklist Individual Strength; IL: interleukin; TNF𝛼: tumor necrosis factor 𝛼; IFN: interferon.
found an association with IL-6 alone and not with the other
immune measures. We were strengthened in our conclusion
by the fact that the association of IL-6 with fatigue was also
called to attention by previous work in an open population
and in other patient populations as we discuss below. As this
was an exploratory study, instead of a confirmatory study
with an increasing number of family-wise null hypotheses to
test, we have refrained from a Bonferroni-like correction to
change the significance level 𝛼 = 0.05 [24].
Furthermore, the cross-sectional design of this study did
not allow the pathophysiological causality of the cytokines to
be established. Blood was drawn between 9:00 and 15:00 and
on average 30 minutes earlier in the fatigued patients com-
pared to the non-fatigued group. Cytokines that are sensitive
to a circadian rhythm should preferably be measured more
than once a day.
Overall, we believe that we have carried out a valid
determination of the (lack of) role of 11 serum cytokines
in primary MS-related fatigue, adjusting for 6 potentially
relevant confounders. In agreement with the trend of our
results, an earlier study found no association between the
Fatigue Severity Scale (FSS) and the systemic inflammation
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variance 𝑅2 Adjustment for confounding by
Pro-inflammatory
cytokines
IL-1𝛽 −2.250 (7.777) −16.407 (10.719) 0.138 0.163 Age, type of MS, duration of MS, EDSS, DMDs
IL-2 −1.345 (6.008) −2.676 (6.996) 0.705 0.019 Type of MS, EDSS, DMDs
IL-6 14.551 (6.748)∗ 19.642 (7.036)∗ 0.009 0.211 Age
IL-8 17.396 (11.875) 17.396 (11.875) 0.152 0.061 —
IL-12p70 1.074 (4.012) −2.292 (5.383) 0.674 0.070 Age, type of MS, EDSS, DMDs
IL-17 8.067 (6.003) 9.011 (6.282) 0.161 0.064 EDSS
TNF-𝛼 6.656 (18.071) 4.950 (18.824) 0.794 0.005 Duration of MS
IFN-𝛾 3.294 (5.806) 3.749 (6.261) 0.554 0.061 Age, type of MS, DMDs
Anti-inflammatory
cytokines
IL-4 −11.081 (11.980) −20.440 (15.070) 0.186 0.106 Age, duration of MS, EDSS
IL-5 −1.479 (4.556) −4.594 (5.673) 0.425 0.092 Age, gender, type of MS, duration of MS, DMDs
IL-10 −2.225 (4.655) −6.806 (5.995) 0.267 0.136 Age, gender, type of MS, duration of MS, EDSS, DMDs
IL-13 −2.804 (5.097) −7.884 (6.467) 0.233 0.113 Age, type of MS, EDSS, DMDs
∗Significant 𝛽.
markers neopterin, C-reactive protein (CRP), and sICAM-
1 in the urine and serum of patients with different MS
subtypes, compared to healthy controls [25]. Our results
contrast with those of some other studies. In whole blood
stimulation experiments involving MS patients with fatigue
compared to MS patients without fatigue, Heesen et al.
showed an elevated productive capacity for TNF-𝛼 and
IFN-𝛾 in the former group [8], whereas IL-10 was not
significantly different between the two patient groups [8].
The discrepancy with our results may be due to the fact
that we measured serum concentrations, whereas the afore-
mentioned study measured stimulated cytokine production
capacity [8]. Others also showed a correlation between
TNF-𝛼 mRNA in serum and fatigue but no correlation of
IFN-𝛾 mRNA with MS-related fatigue [26]. Differences in
capacity to produce cytokines between patients with and
without MS-related fatigue could potentially be explained
by the epigenetic and translational regulation mechanisms
that are also involved in TNF-𝛼 and IFN-𝛾 production
[27].
Othermethodological differences in themeasurements of
fatigue and the determination of cytokines hamper a direct
comparison of studies with regard to the cytokine concentra-
tions and their associationwith fatigue. An example is our use
of theCIS20r subscale fatigue, in contrast to the use of the FSS
in the previously mentioned studies [8, 25, 26]. Although the
FSS is a useful and rapid fatigue screening tool, its main use
is in quantifying the impact of fatigue on daily functioning
rather than ascertaining the perceived level of fatigue [28].
Differences in cytokine detection techniques might also have
contributed to differing study results. For instance, Heesen
et al. [8] used ELISA (enzyme-linked immunosorbent assay)
to analyse cytokines, whereas we used a multiplex kit. Other
possible explanations for divergent findings across studies
may pertain to the specific characteristics of the study
populations.
The pro-inflammatory cytokine IL-6 was the only
immunological marker in our study that was significantly
related to the severity of primary MS-related fatigue after
controlling for confounding. There is considerable evidence
that the serum concentration of IL-6, as well as those of
other cytokines, is influenced by both age and ethnicity [29,
30]. The confounding effect of age on the association of IL-
6 with fatigue observed by us is therefore not specific for
MS. The immunological function of IL-6 is complex and
not exclusively pro-inflammatory [29, 31]. For instance, local
production of IL-6 in the medial hypothalamus and preoptic
nucleus activates the hypothalamic-pituitary-adrenocortical
(HPA) axis and regulates a variety of central effects such as
stress, sleep, and fever [29, 31, 32]. Elevated levels of IL-6 in
the presence of psychological stress were also seen in patients
withMS [33]. A biological measure of stress was not included
in our study. In future studies it is worthwhile to further
investigate the cause and effect relationship of stress, IL-6, and
MS-related fatigue. There is also some evidence from other
studies that IL-6 is associated with fatigue. In a non-medical,
population-based cohort study, the Whitehall II study, high
levels of IL-6 (≥1.5 pg/mL), together with high levels of
plasma C-reactive protein (≥1.0mg/mL), were predictive of
new-onset fatigue in participants (aged 39–63 years) after
a mean follow-up of 3.1 years [11]. From these results it
was concluded that low-grade systemic inflammation may
play an important role in the development of fatigue [11].
Associations between IL-6 and fatigue were also found in
other patient populations [10, 34]. However, no significant
correlations were found between symptoms of fatigue and IL-
6 or C-reactive protein in patients with Parkinson’s disease
[35].
6 Disease Markers
As recently postulated, different MS subtypes could have
different underlying disease mechanisms. It is therefore pos-
sible that primary fatigue experienced within these subtypes
could also be due to different mechanisms [36]. Although
the sample size of the current study was too small to
allow subgroup analyses, future studies should consider the
assessment of each MS subtype with and without perceived
fatigue. Assessing the levels of cytokines in other body fluids,
such as cerebrospinal fluid (CSF), could help to further
unravel the pathophysiological mechanism of MS-related
fatigue. Inflammation is a biological response of the immune
system to a number of different stimuli. If serum levels of
cytokines reflect general systemic inflammation and CSF
levels of cytokines are more closely related to disease-specific
processes in the central nervous system of patients with MS,
simultaneous testing of multiple cytokines in serum and CSF
may shed new light on the possible mechanism of inflamma-
tion in MS-related fatigue. In addition, the concentration of
IL-6 in serum follows a circadian rhythm [29], suggesting that
it might be worthwhile to study the circadian rhythm of IL-
6 compared with the circadian rhythm of fatigue in patients
with MS. Future large longitudinal studies investigating the
causal or etiological role of inflammatorymarkers in primary
MS-related fatigue would be more informative when taking
multiple rather than single blood and CSF samples.
5. Conclusions
This study showed that the pro-inflammatory cytokine
interleukin-6 (IL-6) may play a role in the pathophysiology
of primary fatigue in patients with MS.
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